RxDoctor Payments Data

Catherine Paradiso, APRN

Psychiatric/Mental Health · Punta Gorda, FLNPI 1790089035

Payments from drug & device makers

$1,398in general payments, 2019–2025

Across 30 payments — averaging $46.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$480
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$279
  • Alkermes, Inc.$176
  • Axsome Therapeutics, Inc.$144
  • Livanova USA, Inc.$59
  • Novo Nordisk$47
  • plus $213 from 8 others

What the payments were for

  • Food & beverage$1,34596%
  • Education$534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,398 in reported general payments places this provider in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$48,575
Medicare patients
53
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$18,825
Lurasidone Hcl11$7,500
Aripiprazole13$3,416
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$3,303
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine32$2,911
Duloxetine Hcl92$1,916
Alprazolam131$1,861
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$1,431
Bupropion XlBupropion Hcl85$1,384
Quetiapine Fumarate15$686
Venlafaxine Hcl ErVenlafaxine Hcl41$637
Lorazepam89$529
Clonazepam96$524
Buspirone Hcl35$461
Trazodone Hcl89$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$40$18,82513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Punta Gorda

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →